Intel stock extends gains after report of possible U.S. government stake
On Thursday, Citizens JMP analysts reaffirmed their Market Outperform rating for Madrigal Pharmaceuticals stock (NASDAQ: NASDAQ:MDGL), maintaining a price target of $470.00. This aligns with the broader Wall Street sentiment, as InvestingPro data shows analyst targets ranging from $248 to $540, with a strong buy consensus rating of 1.53. The analysts shared insights into upcoming events that could influence the company’s prospects.
Madrigal Pharmaceuticals is set to host a product theatre titled ’Clinical Deep Dive: Unlocking the Treatment Potential of Rezdiffra’ on Saturday. This event is expected to provide valuable insights into the endocrinology community’s early experiences with Rezdiffra, the first drug for MASH (Metabolic Associated Steatohepatitis).
While no significant new clinical data is anticipated during the event, the conference will include an oral session on Saturday titled ’Liver at the Crossroads: From Molecules to Mechanisms of Metabolic Health.’ This session will explore novel pathways linked to fatty liver disease and potential therapeutic targets.
The analysts are particularly interested in hearing how physicians are identifying MASH within their diabetic populations and the subsequent treatment strategies they employ. These insights could serve as a meaningful boost for Rezdiffra’s market potential, particularly as analysts project significant sales growth for the current year.
In other recent news, Madrigal Pharmaceuticals reported impressive financial results for the first quarter of 2025, significantly surpassing analysts’ expectations. The company achieved earnings per share (EPS) of -3.32, beating the forecasted -3.86, and recorded revenue of $137.3 million, exceeding the anticipated $112.54 million. This marks a 33% increase in revenue quarter-over-quarter, driven by strong demand for their product, ResDiffera. Meanwhile, Citi maintained its Buy rating on Madrigal with a price target of $456, citing positive data from the company’s two-year open-label study presented at the European Association for the Study of the Liver (EASL). In contrast, BofA Securities reiterated its Underperform rating with a $248 price target, expressing concerns over the clarity of benefits and potential downside risks. Madrigal’s management highlighted advancements in their ongoing outcomes trial, expected to provide crucial data by 2027. These developments reflect the company’s growing influence in the NASH treatment market and its strategic expansion efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.